Spark Therapeutics' $4.8B deal confirmed as biggest-ever VC-backed exit in Philly - Technical.ly Philly

Business

Mar. 1, 2019 1:21 pm

Spark Therapeutics’ $4.8B deal confirmed as biggest-ever VC-backed exit in Philly

Quick update on this week's news: The University City life sciences company's acquisition by Swiss pharma giant Roche is the biggest acquisition ever of a VC-backed company within city limits, per PitchBook and PACT.

Founded in 2013, the UCity company announced its acquisition this week.

(Courtesy photo)

The eye-popping $4.8 billion sticker price on Spark Therapeutics’ acquisition deal with Roche announced on Monday is shaping up to be the largest exit ever within city limits for a venture-backed company, according to data from financial data provider PitchBook and the Philadelphia Alliance for Capital and Technologies (PACT).

“Filtering down to just Philadelphia proper does reveal that Spark Therapeutics, once the deal closes, will be the biggest exit ever for Philly-based venture-backed exits,” the company said in an email, citing data from an upcoming report.

According to the Seattle-based company’s data, the current holder of the largest Philly-proper exit title goes to Avid Radiopharmaceuticals, which in 2010 announced its acquisition by Lilly in a deal valued at up to $800 million.

Founded in 2013, Spark is a publicly traded spinout of Children’s Hospital of Philadelphia (CHOP), which invested $33 million in the company. The Philadelphia Inquirer reports that CHOP stands to reap a total return of $430 million for its minority stake in Spark Therapeutics.

As part of the acquisition deal, the company will remain based out of 3711 Market St., and continue to do business as a standalone Roche company.

“This transaction demonstrates the enormous value that global biotech companies like Roche see in gene therapy, a field in which Philadelphia is the unquestioned leader,” said Saul Behar, senior VP of  advancement and strategic initiatives at the University City Science Center, the West Philly research park where Spark began and grew its operations. “[This] further validates Greater Philadelphia’s status as a biotech hub with a very bright future.”

Spark CEO Jeff Marrazzo said the deep pool of resources from Roche, the company plans to “accelerate the development of more gene therapies for more patients for more diseases and further expedite our vision of a world where no life is limited by genetic disease.”

Advertisement

-30-
JOIN THE COMMUNITY, BECOME A MEMBER
Already a member? Sign in here

Advertisement

Should you invest in MBA candidates? This fund thinks yes

BIO 2019 was in Philly this week. Here’s what you missed

Why Ben Franklin Technology Partners is fighting for more state funding

SPONSORED

Philly

This apprenticeship program is opening the door for candidates with nontraditional backgrounds

Philadelphia, PA

Linode

Software Development Engineer in Test

Apply Now
Philadelphia, PA

Linode

Senior Software Engineer – Kubernetes

Apply Now

Biotech company Chondrial Therapeutics has raised $25.8M for its Friedreich’s ataxia treatment

First Round Capital has a big pay day as Uber goes public

Women tech founders: Collaboration can help shrink the venture capital gap

SPONSORED

Philly

How AI can help humans, not replace them

Chesterbrook, PA

Deacom

Software Developer

Apply Now
Philadelphia, PA - Center City

Odessa

Business Analyst – Bilingual (Spanish)

Apply Now
Philadelphia

Macquarie

Senior Cloud Infrastructure Engineer

Apply Now

Sign-up for daily news updates from Technical.ly Philadelphia

Do NOT follow this link or you will be banned from the site!